$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Medical Q&A
Medical Q&A
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Healthcare products
Healthcare products
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Medical Q&A
Medical Q&A
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Healthcare products
Healthcare products
About Us
About Us
Home
Hepatobiliary
Hepatobiliary
乙肝替诺福韦停药研究
2025-10-19 11:44:20
Check Details
乙肝治疗:干扰素是否还有一席之地?
2025-10-19 11:44:20
Check Details
乙型肝炎患者禁食是否安全?
2025-10-19 11:44:20
Check Details
乙肝替诺福韦治疗改善生存率
2025-10-19 11:44:20
Check Details
乙肝母婴传播风险随病毒载量增加
2025-10-19 11:44:20
Check Details
乙肝新联合疗法初见成效
2025-10-19 11:44:20
Check Details
肝移植后乙肝防治:专家问答
2025-10-19 11:44:20
Check Details
慢性乙肝患者产后肝炎发作特点及预测因素
2025-10-19 11:44:20
Check Details
3亿乙型肝炎患者,但只有20%接受治疗
2025-10-19 11:44:20
Check Details
乙肝药物对母婴传播影响不大
2025-10-19 11:44:20
Check Details
乙型肝炎患者禁食是否安全
2025-10-19 11:44:20
Check Details
慢性乙型肝炎患者:肝脏脂肪变性及其对纤维化的影响
2025-10-19 11:44:20
Check Details
1
2
...
99
100
101
102
103
104
105
...
504
505
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Is defibrotide included in medical insurance?
2
When was defibrinoside launched on the market?
3
Will defibrination be reimbursed by medical insurance?
4
What conditions is defibrinoside suitable for treating?
5
What is the therapeutic effect of defibrotide?
6
How should defibrinoside be used?
7
What is the effect of defibrotide?
8
Defibrinoside Detailed Instructions
9
What is the effect of defibrination?
10
How effective is defibrotide in the treatment of hepatic veno-occlusive disease?
11
How effective is defibrotide in hepatic veno-occlusive disease?
12
What conditions can defibrotide treat?